Fig. 2
Immunohistochemical localization of Cy3-galcanezumab (A-B, D-F) and Cy3-bevacizumab (C) in rat trigeminal ganglia 3 days (A, C-F) or 30 days (B) after injection of the antibodies. Arrows indicate blood vessels, arrowheads (A,F) ganglion cells with deposition of fluorophore-labelled galcanezumab. Around * in panel E, capillaries labelled with the anti-von Willebrand factor (vWF) antibody can be seen. SMA: smooth muscle actin